(Corrects to say 25 pct of the company being offered, not 17
pct, in paragraph 3)

* Likely to be S. Korea's third-biggest IPO

* IPO aims to fund production capacity expansion

* Firm also plans 400 bln won investment in Samsung Bioepis

By Joyce Lee and Se Young Lee

SEOUL, Oct 4 Samsung BioLogics Co Ltd, a
contract manufacturer of biotech drugs for global pharmaceutical
firms, said on Tuesday its initial public offering is expected
to raise as much as $2 billion in what is set to be South
Korea's third-largest IPO.

The listing is aimed at helping fund an ambitious expansion
in production capacity to make it the world's largest contract
manufacturer.

The offering of 25 percent of the company is expected to
consist of a new share issue of 11 million shares and the sale
of 5.5 million existing shares by Samsung Electronics Co Ltd
.

With an indicative pricing range of 113,000 won-136,000 won
per share, the offering is expected to raise 2.25 trillion won
($2 billion).

BioLogics said 780 billion won of the proceeds will be used
for factory investment, while another 400 billion won will be
invested in biosimilar drug developer unit Samsung Bioepis.

Samsung Electronics is the second-largest shareholder in
BioLogics after Samsung C&T Corp, the de facto
holding company for the Samsung Group

C&T and related shareholders will own 74.93 percent of the
company after the listing.

BioLogics expects to announce final pricing for the IPO on
Oct. 28.
($1 = 1,103.9000 won)
(Reporting by Joyce Lee and Se Young Lee; Editing by
Muralikumar Anantharaman and Edwina Gibbs)

JOHANNESBURG, Dec 9 A South African motorcyclist
declared dead at the scene of an accident was found alive in a
morgue fridge the next day when his family went to identify his
body, but he died later in hospital.

BERLIN, Dec 9 The European Commission will
propose legislation next year requiring airlines to run mental
health checks on pilots before they start commercial flying, as
part of efforts to prevent a recurrence of last year's
Germanwings crash.